{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:47Z","timestamp":1788153527697,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Once-weekly growth hormone (GH) formulations, such as somatrogon and somapacitan, may reduce the burden of treatment, but injection-site pain can affect treatment preference. Clinical data on patient-reported injection-site pain and preference after switching between once-weekly GH formulations remain limited, particularly in children who experience injection-site pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe changes in perceived injection-site pain and treatment preference after switching from somatrogon to somapacitan in children who reported injection-site pain or discomfort during somatrogon therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective single-arm switch study included 19 children with GH deficiency who had received somatrogon for at least 4 weeks, reported injection-site pain or discomfort during routine clinical care, and agreed to switch to somapacitan. Pain scores for prior somatrogon use and current somapacitan use were assessed once after at least 4 weeks of somapacitan treatment, using the Numerical Rating Scale and\/or Faces Rating Scale according to age. A 5-point Likert questionnaire evaluated device usability, pain at needle insertion, pain during injection, pain after injection, and treatment preference. Paired t-tests and binomial tests were used for the main analyses, and Wilcoxon signed-rank tests were performed as sensitivity analyses for paired pain-score comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 9.6 \u00b1 2.6 years. Diagnoses included isolated GH deficiency (n = 17) and panhypopituitarism after craniopharyngioma surgery (n = 2). Pain scores decreased after switching (Numerical Rating Scale: 6.5 \u00b1 2.6 vs 1.6 \u00b1 1.7; Faces Rating Scale: 3.8 \u00b1 1.1 vs 1.1 \u00b1 1.1; both p &amp;lt; 0.001). All participants preferred continued use of somapacitan (p &amp;lt; 0.001), and questionnaire responses favored somapacitan for pain at needle insertion and pain during injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In children who reported injection-site pain or discomfort during somatrogon therapy and agreed to switch, pain scores and treatment preference improved after switching to somapacitan. These findings support considering a switch to another once-weekly GH formulation when injection-site pain affects treatment preference.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1849487","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:16Z","timestamp":1788150556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Injection-site pain after switching from somatrogon to somapacitan in children reporting pain or discomfort during once-weekly growth hormone therapy: a prospective single-arm switch study"],"prefix":"10.3389","volume":"17","author":[{"given":"Hideyuki","family":"Iwayama","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]},{"name":"Hoshigaoka Growth Clinic","place":["Nagoya, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]},{"name":"Department of Pediatrics, Daiyukai General Hospital","place":["Ichinomiya, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]},{"name":"Department of Pediatrics, Daiyukai General Hospital","place":["Ichinomiya, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takagi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Aichi Medical University","place":["Nagakute, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aichi Medical University","place":["Nagakute, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac220","article-title":"Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A phase 3 study","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000524600","article-title":"Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin\u00ae) in Japanese children with pediatric growth hormone deficiency: Results from a randomized phase 3 study","volume":"95","author":"Horikawa","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae834","article-title":"Long-acting growth hormone therapy in pediatric growth hormone deficiency: A consensus statement","volume":"110","author":"Maniatis","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/cts.13109","article-title":"Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults","volume":"15","author":"Woodley","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B7","unstructured":"NGENLA (Somatrogon-Ghla) Injection, for Subcutaneous Use: US Prescribing Information\n          \n          \n          Silver Spring (MD\n          US Food and Drug Administration\n          \n          2025"},{"key":"B8","unstructured":"SOGROYA (Somapacitan-Beco) Injection, for Subcutaneous Use: US Prescribing Information\n          \n          \n          Silver Spring (MD\n          US Food and Drug Administration\n          \n          2025"},{"key":"B9","unstructured":"Ngenla Subcutaneous Injection 24 Mg\/60 Mg Pens: Japanese Package Insert\n          \n          \n          JAPIC via KEGG MEDICUS\n          \n          2025"},{"key":"B10","unstructured":"Sogroya Subcutaneous Injection: Japanese Package Insert\n          \n          \n          JAPIC via KEGG MEDICUS\n          \n          2025"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.20.47","article-title":"The cubic functions for spline smoothed L, S and M values for BMI reference data of Japanese children","volume":"20","author":"Kato","year":"2011","journal-title":"Clin Pediatr Endocrinol"},{"key":"B12","first-page":"9","article-title":"Pain in children: Comparison of assessment scales","volume":"14","author":"Wong","year":"1988","journal-title":"Pediatr Nurs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-198906000-00005","article-title":"The subjective experience of acute pain. An assessment of the utility of 10 indices","volume":"5","author":"Jensen","year":"1989","journal-title":"Clin J Pain"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/1573397118666220829123713","article-title":"A systematic literature review of injection site pain perception in adult patients treated with citrate-free and citrate-containing biologic agents","volume":"19","author":"Junker","year":"2023","journal-title":"Curr Rheumatol Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1996.tb05892.x","article-title":"Local tolerance of subcutaneous injections","volume":"48","author":"Fransson","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"B16","article-title":"Parenteral dosage forms","volume-title":"Pharmaceutical Preformulation and Formulation","author":"Broadhead","year":"2009"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2011.11.003","article-title":"Variation of pain and vasomotor responses evoked by intramuscular infusion of hypertonic saline in human subjects: Influence of gender and its potential neural mechanisms","volume":"87","author":"Lei","year":"2012","journal-title":"Brain Res Bull"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2026.101705","article-title":"Is somatrogon different? 6-month clinical outcomes and follow-up data in Turkish children transitioned from somatropin to somatrogon","volume":"84","author":"Atas","year":"2026","journal-title":"Growth Hormone IGF Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-015-0242-y","article-title":"A comparison study of patient ratings and safety of 32- and 34-gauge insulin pen needles","volume":"7","author":"Yamada","year":"2016","journal-title":"Diabetol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.963336","article-title":"New insight into the importance of formulation variables on parenteral growth hormone preparations: Potential effect on the injection-site pain","volume":"13","author":"Taghizadeh","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6793.26","article-title":"What makes insulin injections painful","volume":"303","author":"Chantelau","year":"1991","journal-title":"Bmj"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedn.2025.11.021","article-title":"Comparing the effectiveness of cooling and vibrational cooling for pain and fear reduction during insulin injection in children with type 1 diabetes mellitus: A randomized controlled trial","volume":"86","author":"Temu\u00e7in","year":"2026","journal-title":"J Pediatr Nurs"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:19Z","timestamp":1788150559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":22,"alternative-id":["10.3389\/fendo.2026.1849487"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1849487","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1849487"}}